1. Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy’s Law and a New Prognostic Model 
Vincent Lo Re, Kevin Haynes, Kimberly A. Forde, David S. Goldberg, James D. Lewis, Dena M. Carbonari, Kimberly B.F. Leidl, K. Rajender Reddy, Melissa S. Nezamzadeh, Jason Roy, Daohang Sha, Amy R. Marks, Jolanda De Boer, Jennifer L. Schneider, Brian L. Strom, Douglas A. Corley 
Clinical Gastroenterology and Hepatology 
Volume 13, Issue 13, Pages (December 2015)
DOI: /j.cgh
Copyright © 2015 AGA Institute Terms and Conditions

2. Figure 1
Selection of patients in the study. anti-HBc, hepatitis B core antibody; anti-HCV, hepatitis C virus antibody; anti-HDV, hepatitis D virus antibody; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis D virus; IgM, immunoglobulin. *ICD-9 codes or †Index date = first qualifying date of drug-induced liver injury. ‡Patients may have had more than 1 exclusionary diagnosis recorded. §The upper limits of normal of alanine and aspartate aminotransferase were determined by the assay from which each result was measured.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2015 AGA Institute Terms and Conditions